Montecucco Fabrizio, Mach Francois
Division of Cardiology, Foundation for Medical Researches, University Hospital, Geneva, Switzerland.
Endocr Metab Immune Disord Drug Targets. 2008 Dec;8(4):301-7. doi: 10.2174/187153008786848268.
Non alcoholic fatty liver disease (NAFLD) is defined as fat accumulation exceeding 5% to 10% by the weight of the liver, in the absence of other causes of steatosis. NAFLD is strongly associated with metabolic diseases, such as metabolic syndrome. At present, insulin resistance, elevated concentrations of free fatty acids and oxidants, and an imbalance between different cytokines have been identified as the common pathophysiological elements underlying both NAFLD and metabolic syndrome. Emerging evidence also considers NAFLD as the hepatic manifestation of metabolic syndrome and supports a possible direct role of fat liver in cardiovascular risk assessment. Further investigations are needed to better understand the role of NAFLD, as an independent active factor in metabolic syndrome and associated cardiovascular disease.
非酒精性脂肪性肝病（NAFLD）的定义为肝脏脂肪堆积超过肝脏重量的5%至10%，且不存在其他导致脂肪变性的原因。NAFLD与代谢性疾病密切相关，如代谢综合征。目前，胰岛素抵抗、游离脂肪酸和氧化剂浓度升高以及不同细胞因子之间的失衡已被确定为NAFLD和代谢综合征共同的病理生理因素。新出现的证据也将NAFLD视为代谢综合征的肝脏表现，并支持脂肪肝在心血管风险评估中可能发挥的直接作用。需要进一步研究以更好地理解NAFLD作为代谢综合征及相关心血管疾病中一个独立活性因素的作用。
